|
- Aduhelm - ALZFORUM
Aducanumab dose-dependently reduced amyloid deposition in six cortical regions of the brain The effect was large: After one year, the highest dose appeared to have reduced cortical amyloid close to the cut point of positivity
- Lecanemab Bested Three Other Antibodies at Binding Soluble Aβ . . .
Previously, Lars Lannfelt at Uppsala University, Sweden, who started the development of lecanemab, had reported that the antibody bound Aβ protofibrils more strongly than did aducanumab or gantenerumab (Nov 2021 conference news) Lannfelt later compared lecanemab with donanemab, reporting that the two antibodies bound fibrillar amyloid peppered with pyroglutamate-Aβ equally well (Nov 2023
- The antibody aducanumab reduces Aβ plaques in Alzheimers disease . . .
The enthusiasm for aducanumab should rest on its PK, PD, plaque-busting ability, preclinical biochemical characteristics, and clinical safety One doesn’t need to invoke implausible clinical and cognitive effects to make a compelling case for the potential for aducanumab
- Adieu to Aduhelm: Biogen Stops Marketing Antibody - ALZFORUM
Biogen has thrown in the towel on its controversial anti-amyloid antibody aducanumab The company announced January 31 that it would stop all development of the drug, and halt the post-market, confirmatory Envision trial Aducanumab was originally licensed from Swiss company Neurimmune, and the
- Kinetic fingerprints differentiate the mechanisms of action . . . - ALZFORUM
The authors report data on mouse versions of four clinical antibodies, namely aducanumab, bapineuzumab, solanezumab and gantenerumab The side-by-side comparison of these therapeutics adds weight to this study because kinetic studies of amyloid are highly susceptible to misinterpretation owing to the pleiomorphic and temperamental nature of the ligand
- A New Era of Alzheimer’s Treatment - ALZFORUM
For example, Ken Marek at the Institute for Neurodegenerative Disorders in New Haven, Connecticut, believes the aducanumab decision heralds the beginning of a new era in neurodegenerative disease research, with a focus on therapies that move biomarkers in Alzheimer's and related diseases and slow the march of the underlying pathology (STAT news)
- Clinical Trials on Alzheimers Disease (CTAD) 2022 - ALZFORUM
The top-line results last September from Eisai’s Phase 3 trial of the anti-amyloid antibody lecanemab galvanized the field, but scientists said they needed to see the data before passing judgement Now they have At the 15th Clinical Trials on Alzheimer’s Disease conference, held November 29 to December 2 in San Francisco and online, scientists presented detailed findings to a standing
- Aducanumab Still Needs to Prove Itself, Researchers Say
Because aducanumab has to be infused, expense and logistics are also considerations “We presently are woefully unprepared to incorporate any truly effective therapy into clinical practice,” John Morris at Washington University wrote to Alzforum Clinics will need new resources and training to enable them to diagnose and treat patients
|
|
|